LEADS BIOLABS-B (09887) announces its interim financial results. Net loss is approximately 166 million yuan, a decrease of 7.8% year-on-year.

LEADS BIOLABS-B(09887) announced its mid-year performance for 2025, with research and development costs of approximately 132 million yuan, a year-on-year increase of 56.9%; a loss of approximately 166 million yuan during the period, a decrease of 7.8% year-on-year; and a loss per share of 1.06 yuan. The announcement stated that the increase in research and development costs was mainly due to: (i) an increase in CMC development milestone expenses, mainly related to preparatory work for the submission of the Biological License Application (BLA) for LBL-024; and (ii) an increase in clinical development expenses, mainly due to accelerated patient enrollment and clinical progress for LBL-024 and LBL-034.